Summary
Hairless mice were immunized with herpes simplex virus type 1 (HSV-1) envelope antigen (EAG), EAG in association with polyriboinosinic · polyribocytidylic acid-poly-L-lysine complexed with carboxymethylcellulose (PICLC), and inactivated purified HSV-1 (VAG). After 2 weeks the mice were challenged by a percutaneous HSV-1 infection in the orofacial (OF) or lumbosacral (LS) skin area. Following immunization a consistent cell-mediated immune response was observed in all immunized mice, although the humoral immune response was very low, or not detectable. After challenge, a marked secondary humoral and cell-mediated immune response developed in all immunized mice, and the animals were protected against the development of skin lesions and the fatal outcome of infection. However, the establishment of latent infections in the sensory ganglia was not prevented by the immunization procedure.
Similar content being viewed by others
References
Brown, S. M., Subak-Sharpe, J. H., Warren, K. G., Wroblewska, Z., Koprowski, H.: Detection by complementation of defective or uninducible (herpes simplex type 1) virus genomes latent in human ganglia. Proc. Nat. Acad. Sci. U.S.A.76, 2364–2368 (1979).
Cappel, R., de Cuyper, F., Rickaert, F.: Efficacy of a nucleic acid free herpetic subunit vaccine. Arch. Virol.65, 15–24 (1980).
Duff, R., Rapp, F.: Oncogenic transformation of hamster embryo cells after exposure to inactivated herpes simplex virus type 1. J. Virol.12, 209–217 (1973).
Forghani, B., Klassen, T., Baringer, J. R.: Radioimmunoassay of herpes simplex virus antibody: correlation with ganglionic infection. J. gen. Virol.36, 371.
Kitces, E. N., Morahan, P. S., Twe, J. G., Murray, B. K.: Protection from oral herpes simplex infection by a nucleic acid-free virus vaccine. Infect. Immun.16, 955–960 (1977).
Klein, R. J., Friedman-Kien, A. E., Fondak, A. A., Buimovici-Klein, E.: Immune response and latent infection after topical treatment of herpes simplex virus infection in hairless mice. Infect. Immun.16, 842–848 (1977).
Kutinova, L., Slichtova, V., Vonka, V.: Immunogenicity of subviral herpes simplex virus preparations. Arch. Virol.61, 141–148 (1979).
McCombs, R. M.: Concentration and purification of herpes virus (simplex, cytomegalo, and EB) in a zonal ultracentrifuge. Appl. Microbiol.17, 636–638 (1969).
Notkins, A. L., Bankowski, R. A., Baron, S.,et al.: Workshop on the treatment and prevention of herpes simplex virus infections. J. inf. Dis.127, 117–119 (1980).
Rajcani, J., Kutinova, L., Vonka, V.: Restriction of latent herpes simplex virus infection in rabbits immunized with subviral herpes simplex virus vaccine. Acta Virol.24, 183–193 (1980).
Rawls, W. E., Tompkins, W. A. F., Melnick, J. L.: The association of herpesvirus type 2 and carcinoma of the uterine cervis. Amer. J. Epidemiol.89, 547–554 (1969).
Scriba, M.: Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous herpes simplex virus: implications for a herpes virus vaccine. Med. Microbiol. Immunol.166, 63–69 (1978).
Skinner, G. R. B., Williams, D. R., Moles, A. W., Sargent, A.: Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus. Arch. Virol.64, 329–338 (1980).
Spear, P. B., Roizman, B.: Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpes virion. J. Virol.9, 143–159 (1972).
Wise, T. G., Pavan, P. R., Ennis, F. A.: Herpes simplex virus vaccines. J. inf. Dis.136, 706–711 (1977).
Author information
Authors and Affiliations
Additional information
With 2 Figures
Rights and permissions
About this article
Cite this article
Klein, R.J., Buimovici-Klein, E., Moser, H. et al. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice. Archives of Virology 68, 73–80 (1981). https://doi.org/10.1007/BF01314437
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01314437